LMF Acquisition Opportunities Inc. Warrant (ICUCW)
Market Closed
11 Jun, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 02
+0
+4.2424%
Pre Market
$
+0 +16.2791% 0. 02
677.68K Market Cap
- P/E Ratio
- Div Yield
70,988 Volume
-1.15 Eps
$ 0.02
Previous Close Investors:
Want to track ICUCW and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ICUCW closed today higher at $0.02, an increase of 4.2424% from yesterday's close, completing a monthly decrease of -42.2819% or -$0.01. Over the past 12 months, ICUCW stock gained 66.9903%.
ICUCW is not paying dividends to its shareholders.
The last earnings report, released on Mar 26, 2026, exceeded the consensus estimates by 1.08%. On average, the company has surpassed earnings expectations by 1.08%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.
LMF Acquisition Opportunities Inc. Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 46,690 | $1,265.29 | $933.8 | -$331.49 | -26.2% |
LMF Acquisition Opportunities Inc. Warrant (ICUCW) FAQ
What is the stock price today?
The current price is $0.02.
On which exchange is it traded?
LMF Acquisition Opportunities Inc. Warrant is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is ICUCW.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 677.68K.
Has LMF Acquisition Opportunities Inc. Warrant ever had a stock split?
No, there has never been a stock split.
LMF Acquisition Opportunities Inc. Warrant Profile
| Biotechnology Industry | Healthcare Sector | Eric Schlorff CEO | NASDAQ (CM) Exchange | 81256L112 CUSIP |
| US Country | 19 Employees | - Last Dividend | - Last Split | 28 Oct 2022 IPO Date |
Overview
SeaStar Medical Holding Corporation is a prominent medical device company based in the United States, specifically headquartered in Denver, Colorado. They are at the forefront of developing innovative platform therapies aimed at mitigating the impacts of hyperinflammation on critical organs. The company's core mission revolves around harnessing the body's natural inflammatory response to combat infections and facilitate the healing of damaged tissue. This focus positions SeaStar Medical as a key player in addressing complex medical conditions associated with excessive inflammation.
Products and Services
SeaStar Medical Holding Corporation is engaged in the development of cutting-edge products across various therapeutic areas. These include:
- Pediatric and Adult Acute Kidney Injury on CRRT: Developing treatments to address acute kidney injury (AKI) in both pediatric and adult patients undergoing Continuous Renal Replacement Therapy (CRRT), aiming to improve outcomes and recovery rates.
- Cardiorenal Syndrome in Congestive Heart Failure: Focusing on innovative solutions for patients suffering from cardiorenal syndrome, a condition that complicates congestive heart failure by affecting the heart and kidneys simultaneously, thereby enhancing patient care and management.
- Myocardial Stunning in End Stage Renal Disease: Working on therapies for myocardial stunning, a temporary reduction in the heart's pumping function occurring in patients with end-stage renal disease (ESRD), seeking to improve cardiac function and patient quality of life.
- Hepatorenal Syndrome: Developing treatments for hepatorenal syndrome, a severe condition that develops in patients with advanced liver disease and deteriorates kidney function, aiming to offer hope and new solutions for these critically ill patients.
Contact Information
Address: 3513 Brighton Boulevard
Phone: 844 427 8100
Website: https://www.seastarmedical.com
